Study of the Role of Genetic Modifiers in Hemoglobinopathies

Clinical trial NCT05799118 · RECRUITING

Trial details

NCT number: NCT05799118
Sponsor: Cyprus Institute of Neurology and Genetics
Status: RECRUITING
Study type: OBSERVATIONAL

Sickle Cell Disease Thalassemia, Beta Thalassemia Alpha Hemoglobinopathies

Start date: 2022-10-01
Primary completion: 2027-09-30
Enrollment: 30000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.